Literature DB >> 2842096

Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus.

T Mathiesen1, M A Persson, V A Sundqvist, B Wahren.   

Abstract

IgG subclasses 1, 3 and 4 in sera from herpes simplex virus type 1 (HSV-1) seropositive donors were separated and their functions assayed. The main neutralizing activity to HSV-1 was found in the IgG1 fractions. Both IgG3 and IgG4 possessed higher neutralizing titres than IgG1 in relation to the respective HSV IgG subclass enzyme-linked immunosorbent assay (ELISA) titre. Addition of complement resulted in a strong enhancement of IgG3 neutralizing activity. HSV neutralizations by IgG1 and, surprisingly, IgG4 were also somewhat enhanced by complement. With the addition of complement, the contribution to neutralizing activity of IgG3 was calculated to increase from 31 to 40% of total IgG in HSV neutralization in native sera. The avidities of the IgG fractions to HSV glycoprotein C (gC) were estimated in a few sera but could not be correlated to neutralization results. Antibody dependent cell-mediated cytotoxicity (ADCC) was detectable mainly in IgG1 and 3 fractions of sera with high anti-HSV antibody titres.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2842096      PMCID： PMC1541526     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  22 in total

1.  Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.

Authors:  B Norrild; S L Shore; A J Nahmias
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

3.  Use of protein A-treated sera in unmasking herpes simplex virus type 1 (HSV-1) immunoglobulin A and identifying HSV-1 immunoglobulin G as the predominant neutralizing antibody.

Authors:  J J Ratner; B A Sanford; K O Smith
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

4.  The binding of human IgG subclasses to human monocytes.

Authors:  F C Hay; G Torrigiani; I M Roitt
Journal:  Eur J Immunol       Date:  1972-06       Impact factor: 5.532

5.  Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway.

Authors:  A Ehrnst
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

6.  The reaction of monomeric and aggregated immunoglobulins with C1.

Authors:  W Augener; H M Grey; N R Cooper; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1971-11

7.  Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells.

Authors:  S Kohl; S E Starr; J M oleske; S L Shore; R B Ashman; A J Nahmias
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

8.  Comparison of antibody-dependent cellular cytotoxicity and complement-dependent antibody lysis of herpes simplex virus-infected cells as methods of detecting antiviral antibodies in human sera.

Authors:  T Subramanian; W E Rawls
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

9.  Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement.

Authors:  V N Schumaker; M A Calcott; H L Spiegelberg; H J Müller-Eberhard
Journal:  Biochemistry       Date:  1976-11-16       Impact factor: 3.162

10.  H CHAIN SUBGROUPS OF MYELOMA PROTEINS AND NORMAL 7S GAMMA-GLOBULIN.

Authors:  H M GREY; H G KUNKEL
Journal:  J Exp Med       Date:  1964-08-01       Impact factor: 14.307
View more
  8 in total

1.  Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3.

Authors:  A Linde; R Söderström; C I Smith; M Sällberg; H Dahl; R Grubb; J Björkander; L Hammarström
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides.

Authors:  T Mathiesen; P A Broliden; J Rosen; B Wahren
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

3.  Errors in data interpretation from genetic variation of human analytes.

Authors:  Heather L Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Linda Kapp; Jenna N Lebedev; James C Zimring
Journal:  JCI Insight       Date:  2017-07-06

4.  Analysis of a subclass-restricted HIV-1 gp41 epitope by omission peptides.

Authors:  T Mathiesen; F Chiodi; P A Broliden; J Albert; R A Houghten; G Utter; B Wahren; E Norrby
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

5.  Specific IgG subclass reactivity in herpes simplex encephalitis.

Authors:  T Mathiesen; A Linde; E Olding-Stenkvist; B Wahren
Journal:  J Neurol       Date:  1988-09       Impact factor: 4.849

6.  Antibody to Mycobacterium tuberculosis 65 kDa heat shock protein in patients with rheumatoid arthritis--a survey of antigen-specific antibody isotypes and subclasses in an endemic area of previous tuberculosis infection.

Authors:  N S Lai; J L Lan; C L Yu; R H Lin
Journal:  Ann Rheum Dis       Date:  1995-03       Impact factor: 19.103

7.  Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.

Authors:  O H Negm; B MacKenzie; M R Hamed; O A J Ahmad; C C Shone; D P Humphreys; K Ravi Acharya; C E Loscher; I Marszalowska; M Lynch; M H Wilcox; T M Monaghan
Journal:  Clin Exp Immunol       Date:  2017-03-16       Impact factor: 4.330

8.  Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Mol Vis       Date:  2010-01-26       Impact factor: 2.367
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.